HSA-based polymeric NPs coated with cancer membrane proteins for specific targeting are potentially nontoxic to normal cells and exhibit site-directed delivery with long-lasting therapeutic effects against brain tumors. The gene discussed is ALB; the disease is brain neoplasm.